Article Text

Download PDFPDF
Short term coseasonal sublingual immunotherapy reduced the development of asthma in children with hay fever

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

Q In children with allergic rhinoconjunctivitis (hay fever), does short term coseasonal sublingual immunotherapy reduce the development of asthma and seasonal hay fever symptoms?


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {patients, healthcare providers, and data collectors}*.

Embedded ImageFollow up period:

3 years.

Embedded ImageSetting:

6 paediatric allergy centres in North Central Italy (Emilia, Tuscany, and Lazio).

Embedded ImagePatients:

113 children 4–16 years of age (mean age 8 y) with hay fever caused by grass pollen and clinical monosensitisation to grass pollen. Exclusion criteria: asthma, clinical sensitisation to other inhalant allergens, and previous immunotherapy …

View Full Text


  • * Information provided by author.

  • For correspondence: Dr S E Burastero, San Raffaele Scientific Institute, Milano, Italy.

  • Source of funding: no external funding.